Identification, Screening and Mechanism Analysis of Anti-Parkinson's Disease Peptides from

Qingzhong Wang, Shuqin Shao, Yizhuo Wang, Wenshuai Fan, Zilong Wang, Xuchang Liu, Kechun Liu, Shanshan Zhang

Abstract read

In one paragraph

Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qingzhong WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Shuqin ShaoBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Yizhuo WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Wenshuai FanBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Zilong WangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Xuchang LiuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Kechun LiuBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.

Shanshan ZhangBiology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China.ORCID 0000-0002-2104-9909

Funding

National Natural Science Foundation of China 42006090Shandong Provincial Natural Science Foundation ZR2025MS622

6 · The paper itself

Abstract

At present, there is still a lack of effective treatments to slow the progression of Parkinson's disease. Naturally derived active substances, valued for their safety and multi-target potential, have become an important direction in anti-PD drug development, with marine organisms representing a valuable source of bioactive peptides. This study aimed to isolate and identify anti-PD peptides from

Indexed as

Antiparkinson AgentsNeuroprotective AgentsParkinson DiseasePeptidesProtein HydrolysatesAnimalsBioactive Peptides, DietaryDisease Models, AnimalDopaminergic NeuronsHumansMolecular Docking SimulationOxidative StressSnailsZebrafishAntiparkinson AgentsBioactive Peptides, DietaryNeuroprotective AgentsPeptidesProtein Hydrolysatesanti-Parkinson’s disease activitymolecular dockingpeptideRapana venosaTranscriptome sequencingzebrafish

Identifiers

PMID42188315

DOI10.3390/md24050180

PMCPMC13208443

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.